Relapsed or Refractory Acute Myeloid Leukemia Clinical Trial
Official title:
A Single-arm Open-label Multicenter Clinical Study of Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia
This clinical trial studies the efficacy and safety of selinexor combined with HAD or CAG regimen in the treatment of relapsed or refractory acute myeloid leukemia
Main Purpose： To observe the efficacy of selinexor in combination with HAD or CAG regimen for relapsed and refractory acute myeloid leukemia :complete remission rate (CR rate), partial remission rate (PR rate), no remission rate (NR rate), complete remission with incomplete hematologic recovery(CRi rate) Secondary Purposes： 1. To observe the recurrence rate of selinexor combined with HAD or CAG regimen for relapsed and refractory acute myeloid leukemia, treatment-related mortality(TRM), Overall Survival (OS), Event-Free Survival (EFS); 2. Safety indicators: to observe adverse events and deaths during treatment with selinexor in combination with HAD or CAG regimen. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04478695 -
Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia
|
Phase 1 | |
| Terminated |
NCT05038800 -
A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002)
|
Phase 1 | |
| Completed |
NCT04176393 -
A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation
|
Phase 1 | |
| Recruiting |
NCT03850574 -
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04666649 -
Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)
|
Phase 1 | |
| Recruiting |
NCT04842370 -
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of AML
|
Phase 1 | |
| Active, not recruiting |
NCT02675452 -
AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia
|
Phase 1 | |
| Recruiting |
NCT05522192 -
Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia
|
Phase 1/Phase 2 | |
| Completed |
NCT03755154 -
Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
| Recruiting |
NCT03765541 -
Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia
|
Phase 3 | |
| Recruiting |
NCT05787496 -
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
|
Phase 1 | |
| Terminated |
NCT02623582 -
CD123 Redirected Autologous T Cells for AML
|
Early Phase 1 | |
| Withdrawn |
NCT02215629 -
Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia
|
Phase 1 |